# Immune Reconstitution to CMV After HSCT: Impact of Clinical Factors and Therapy Strategies

> **NCT05656599** · — · UNKNOWN · sponsor: **Peking University People's Hospital** · enrollment: 120 (estimated)

## Conditions studied

- CMV Infection
- Hematopoietic Stem Cell Transplantation

## Interventions

- **DRUG:** Letermovir

## Key facts

- **NCT ID:** NCT05656599
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-03
- **Primary completion:** 2024-12
- **Final completion:** 2025-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05656599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05656599, "Immune Reconstitution to CMV After HSCT: Impact of Clinical Factors and Therapy Strategies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05656599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*